WHWeng-Foung Huang

Weng-Foung Huang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Weng-Foung Huang has a total of 39 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Pharmaceutical Benefit Scheme and Cost Containment in Taiwan's National Health Insurance

    by Weng-Foung Huang, Hung-Chi Chiang

    Since Taiwan launched its mandatory National Health Insurance (NHI) on March 1 1995, the growth of pharmaceutical expenditures has far exceeded that of other NHI benefit expenditures. It remained around 25% of total medical expenditures until 2002. The Bureau of NHI has adopted several strategies to contain the escalating pharmaceutical expenditures over the past couple of years. This article describes the background of Taiwan’s NHI, its current status, pharmaceutical benefit scheme, pricing control and cost containment measures. It also delineates in detail the strategies taken, including co-payment of prescription medicines, price volume survey, generic grouping, restrictive guidance on new drug indications, and payment reforms so far. Regardless of measures taken by the Bureau of NHI, there are issues 133 134that remain unsolved. The scope of the pharmaceutical benefits scheme remained to be clearly defined. There is no consensus whether reimbursement should be based only on active pharmaceutical ingredients. Other unsolved issues include the payment gap between the reimbursement price and acquisition cost, strategies of co-payment, transparency of the price setting mechanism, and rewards for innovations. It is advocated that any issues on pharmaceutical cost containment should be subject to more transparency and public scrutiny in order to be accountable to all stakeholders. [Article copies available for a fee from The Haworth Document Delivery Service: 1-800-HAWORTH. E-mail address: <[email protected]> Website: Ó 2003 by The Haworth Press, Inc. All rights reserved.]

  • Open Access

    A Nationwide Cohort Study of Actinic Keratosis in Taiwan

    by Chi-Feng Hsieh, Yi-Ting Chiang, Hsien-Yi Chiu, Weng-Foung Huang

    Background: Incidence of actinic keratosis (AKs) and nonmelanoma skin cancer appears to be increasing worldwide due to increasing levels of ultraviolet radiation, lifestyle changes, and an aging population. However, there is no population-based study focusing on AKs among Asian population. We aimed to investigate the incidence, the treatment pattern, the medical utilization and the risk of malignant neoplasm of the AKs patients in Taiwan. Methods: We conducted a retrospective cohort study to investigate patients with AKs from 2003 to 2011 by using the National Health Insurance Research Database (NHIRD). The inclusion criteria were patients who had at least two outpatient visits or one hospital admission of AK identified by dermatologist from 2004 to 2011. There were 35,933 patients with AKs (elderly [aged ≥65 years]: n = 17,004; non-elderly [aged <65 years]:18,929 patients). Results: We found the incidence rate for AKs among elderly patients was higher than non-elderly. We further found that there were 923 patients were identified skin malignant neoplasm after diagnosis of AKs, and the incidence rate among elderly patients was higher than non-elderly (122.66 vs. 13.80 per 10,000 patient-year). Conclusions: The AKs incidence rate was low in general population but particular high in elderly population in Taiwan. Our findings warrants further investigation into the relationship between actinic keratosis and the nonmelanoma skin cancer (NMSC) in Asians and may affect the approach toward primary prevention of NMSC in Asians with AKs.


  • Risk of fractures in vitiligo patients treated with phototherapy—A retrospective population-based cohort study

    by Po-Ching Lo, Cheng-Yuan Li, Weng-Foung Huang, Yi-Wen Tsai, Han-Nan Liu, Yun-Ting Chang, Hsien-Yi Chiu, Tsen-Fang Tsai


  • Open Access

    Prolonged risk of subtrochanteric and diaphyseal femur fractures after discontinuing alendronate treatment: A nationwide nested case-control study in Taiwan

    by Weng-Foung Huang, Li-Chuang Chang, Yu-Hsiang Kao, Yu-Wen Wen, Fei-Yuan Hsiao, Li-Ning Peng, Yi-Wen Tsai, Liang-Kung Chen

  • Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan

    by Hsien-Yen Chang, Chi-Feng Hsieh, Sonal Singh, Wenze Tang, Yi-Ting Chiang, Weng-Foung Huang

    Aims To examine the relationship between different anti-diabetic therapies (dipeptidyl peptidase-4 (DPP-4), metformin and sulfonylureas) and risk of acute pancreatitis among type 2 diabetic patients in Taiwan, and explore each drug's dose-response relationship. Materials and Methods We derived a nationwide retrospective cohort of patients with type 2 diabetes in Taiwan. The inclusion criteria are adult diabetic patients with continuous baseline enrollment, new users of the studied drugs, and without missing demographics. There were 4113/101 498/44 772 DPP-4/Metformin/Sulfonylurea users. Adjusted hazards ratios for pancreatitis associated with DPP-4, derived from Cox proportional hazard models with propensity score weighting, were estimated; dose-response analyses were also conducted. Results Dipeptidyl peptidase-4 was statistically significantly associated with a decreased risk of acute pancreatitis compared with sulfonylureas (adjusted HR: 0.36, 95%CI [0.17, 0.75]) but not metformin (adjusted HR: 0.67, 95%CI [0.32, 1.41]); metformin was statistically significantly associated with a lower risk of pancreatitis than sulfonylurea (adjusted HR: 0. 53; 95%CI [0.37, 0.76]). In addition, low-dose metformin was statistically significantly associated with a lower risk of pancreatitis compared with high-dose metformin (HR: 0.65; 95%CI [0.44, 0.97]). Conclusions Our findings suggest that sulfonylureas may potentially be associated with an increased risk of pancreatitis compared with DPP-4 or metformin. Studies with longer follow up, larger sample sizes, and more precise capture of confounders may be needed to determine the risk of pancreatitis associated with incretin based therapies. Copyright © 2015 John Wiley & Sons, Ltd.


  • Open Access

    The patterns of outpatient off-label carbamazepine use and the potential impact of regulatory labelling process in Taiwan

    by Chi-Feng Hsieh, Po-Ying Chang, Pei-Yu Lu, Weng-Foung Huang

    Background Carbamazepine has been associated with severe cutaneous adverse drug reactions (ADR). It is important for patients with these ADRs under off-label prescriptions are not eligible for drug injury relief in Taiwan. We conducted a study to depict the demography and possible factors related to the off-label carbamazepine use in Taiwan. We also explored the policy influence of carbamazepine use. Methods We used the dataset of one million randomly-sampled insured persons in the Taiwan National Health Insurance Research Database for 2002 and 2006 to conduct a cross-sectional study. With the use of a computerized clinical information system, carbamazepine prescriptions were categorized into five groups (A, B, C, D and E) according to these indications: Group A, B were defined as on-label use; group C, D and E were defined as various levels of off-label use, depending on the strength of support from the literature. A logistic regression model was conducted to find the factors related to off-label use. Results Based on the one million representative samples, 6305 and 5703 patients received 31 146 and 27 579 carbamazepine prescriptions in 2002 and 2006 respectively. In both years, nearly 43% of total prescriptions were related to on-label uses. Prescriptions from primary clinics and departments of internal medicine and psychiatry, the physician's age, and the patient's age were factors associated with higher risk of off-label carbamazepine use. Conclusions Our study echoes the highly prevalent off-label use of carbamazepine in Taiwan and adds to the rare research on this subject in the East Asian population. The carbamazepine relabelling in 2004 did not change either prescription patterns or factors related to off-label use.


  • Effect of Helicobacter pylori Eradication Therapy on Risk of Hospitalization for a Major Ulcer Event

    by Fei‐Yuan Hsiao, Yi‐Wen Tsai, Yu‐Wen Wen, Ken N. Kuo, Chia‐Rung Tsai, Weng‐Foung Huang

    Study Objective. To compare Helicobacter pylori eradication therapy with antisecretory therapy aloneonthe riskofhospitalization for a major ulcer event.Design. Retrospective, population‐based cohort study.Data Source. The 2000–2006 National Health Insurance database in Taiwan.Patients. A total of 838,176 patients diagnosed with a gastrointestinal ulcer and who filled at least one prescription for antiulcer therapy, either H. pylori eradication therapy (331,364 patients [39.53%])orantisecretory therapy alone (506,812 patients [60.47%]), between January1, 2001, and December 31, 2006.Measurements and Main Results. The primary outcome was hospitalization for a major ulcer event, defined as a gastrointestinal ulcer with hemorrhage and/or perforation. Cox proportional hazards models, adjusted for demographic and clinical characteristics, were used to compare the risk of hospitalization for a major ulcer event between the group receiving H. pylori eradication therapy (triple or quadruple combination therapy that includes an antisecretory agent) and the group receiving antisecretory therapy alone (histamine2‐receptor blocker or proton pump inhibitor). The H. pylori eradication therapy group was divided into initial users (combination therapy received immediately after gastrointestinal ulcer diagnosis) and late users (combination therapy received after antisecretory therapy with time lag≤180 days, 181–365 days, or>365 days from ulcer diagnosis). A secondary analysis was conductedinthe three late H. pylorieradication therapy subgroups to determine if risk of hospitalization for major ulcer events differed by timing of receipt of therapy. Compared with the antisecretory therapy alone group, the H. pylori therapy group (initial users) had a significantly decreased risk of hospitalization for major ulcer events (adjusted hazard ratio [AHR] 0.57, 95% confidence interval [CI] 0.54–0.59, pH. pylori therapy was associated with a higher riskofhospitalization for major ulcer events (time lag 181–365 days, AHR 1.68, 95%CI1.51–1.86, p365 days, AHR 1.74, 95% CI1.67–1.80, pH. pylori therapy within6months(≤180 days) after gastrointestinal ulcers were diagnosed.Conclusion. Helicobacter pyloritherapy given within 6 months of a diagnosis of gastrointestinal ulcer was associated with a reduced risk of hospitalization for major ulcer events. Our findings extend the evidence from clinical trials that report the value ofH. pylori eradication therapy in reducing ulcer recurrence by documenting the real‐world benefit of reducing the risk of hospitalization for major gastrointestinal ulcer events.


  • Open Access

    Diffusion patterns of new anti-diabetic drugs into hospitals in Taiwan: the case of Thiazolidinediones for diabetes

    by Yu-Wen Wen, Weng-Foung Huang, Yue-Chune Lee, Ken N Kuo, Chia-Rung Tsai, Yi-Wen Tsai

    Background: Diffusion of new drugs in the health care market affects patients' access to new treatment options and health care expenditures. We examined how a new drug class for diabetes mellitus, thiazolidinediones (TZDs), diffused in the health care market in Taiwan. Methods: Assuming that monthly hospital prescriptions of TZDs could serve as a micro-market to perform drug penetration studies, we retrieved monthly TZD prescription data for 580 hospitals in Taiwan from Taiwan's National Health Insurance Research Database for the period between March 1, 2001 and December 31, 2005. Three diffusion parameters, time to adoption, speed of penetration (monthly growth on prescriptions), and peak penetration (maximum monthly prescription) were evaluated. Cox proportional hazards model and quantile regressions were estimated for analyses on the diffusion parameters. Results: Prior hospital-level pharmaceutical prescription concentration significantly deterred the adoption of the new drug class (HR: 0.02, 95%CI = 0.01 to 0.04). Adoption of TZDs was slower in district hospitals (HR = 0.43, 95%CI = 0.24 to 0.75) than medical centers and faster in non-profit hospitals than public hospitals (HR = 1.79, 95%CI = 1.23 to 2.61). Quantile regression showed that penetration speed was associated with a hospital's prior anti-diabetic prescriptions (25%Q: 18.29; 50%Q: 25.57; 75%Q: 30.97). Higher peaks were found in hospitals that had adopted TZD early (25%Q: -40.33; 50%Q: -38.65; 75%Q: -32.29) and in hospitals in which the drugs penetrated more quickly (25%Q: 16.53; 50%Q: 24.91; 75%Q: 31.50). Conclusions: Medical centers began to prescribe TZDs earlier, and they prescribed more TZDs at a faster pace. The TZD diffusion patterns varied among hospitals depending accreditation level, ownership type, and prescription volume of Anti-diabetic drugs.


  • Open Access

    Price regulation, new entry, and information shock on pharmaceutical market in Taiwan: a nationwide data-based study from 2001 to 2004

    by Fei-Yuan Hsiao, Yi-Wen Tsai, Weng-Foung Huang

    Background: Using non-steroidal anti-inflammatory drugs (NSAIDs) as a case, we used Taiwan's National Health Insurance (NHI) database, to empirically explore the association between policy interventions (price regulation, new drug entry, and an information shock) and drug expenditures, utilization, and market structure between 2001 and 2004. Methods: All NSAIDs prescribed in ambulatory visits in the NHI system during our study period were included and aggregated quarterly. Segmented regression analysis for interrupted time series was used to examine the associations between two price regulations, two new drug entries (cyclooxygennase-2 inhibitors) and the rofecoxib safety signal and expenditures and utilization of all NSAIDs. Herfindahl index (HHI) was applied to further examine the association between these interventions and market structure of NSAIDs. Results: New entry was the only variable that was significantly correlated with changes of expenditures (positive change, p = 0.02) and market structure of the NSAIDs market in the NHI system. The correlation between price regulation (first price regulation, p = 0.62; second price regulation, p = 0.26) and information shock (p = 0.31) and drug expenditure were not statistically significant. There was no significant change in the prescribing volume of NSAIDs per rheumatoid arthritis (RA) or osteoarthritis (OA) ambulatory visit during the observational period. The market share of NSAIDs had also been largely substituted by these new drugs up to 50%, in a three-year period and resulted in a more concentrated market structure (HHI 0.17). Conclusions: Our empirical study found that new drug entry was the main driving force behind escalating drug spending, especially by altering the market share.